Equity Profile

LQDA

Liquidia Corporation

Health CarePharmaceuticals$6.5B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Liquidia Corporation is a pharmaceutical company focused on developing innovative treatments for patients with serious diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as demand for advanced medical solutions grows.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will look for signs of revenue growth as a measure of the company's market performance and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LQDA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+21.08%

Avg Stock Reaction

+4.49%

Last Quarter Recap

In Q1 2026, Liquidia reported an EPS of $0.52, significantly beating expectations of $0.34, which led to a 25.6% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Focus on expanding product offerings in the respiratory market.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiencies to improve margins.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown strong EPS surprises in recent quarters, but revenue guidance remains unclear. Investors are eager to see if this trend continues.

Bull Case

If Liquidia can demonstrate continued profitability and strong revenue growth, it could solidify investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a sell-off as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue for this quarter?

Revenue figures are crucial for assessing the company's growth trajectory and market acceptance of its products.

Will management provide guidance on future earnings?

Clear guidance can significantly influence investor sentiment and expectations for the upcoming quarters.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Liquidia's new product pipeline to drive significant revenue growth, given the recent positive EPS surprises.

Supporting Evidence

Liquidia has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a large move, suggesting traders expect a significant reaction that the consensus may not fully reflect.

The company's focus on expanding into new therapeutic areas could provide unexpected revenue streams.

Key Risk

If the reported revenue significantly exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether the recent positive EPS surprises can translate into sustained revenue growth.

Bull Confirmed If

Reporting revenue growth exceeding 20% year-over-year would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or lack of guidance would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±29.39%

Historical Avg

±6.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.4% while LQDA has averaged ±6.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

78.5%

Calls (67K)P/C Ratio: 0.18Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Liquidia beats expectations and raises guidance, history suggests a potential stock increase of around 6.54%, reinforcing bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 2.44%, leading to increased skepticism about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth and product sales in the respiratory market.
2Management's outlook on future earnings and any guidance provided.
3Updates on clinical trials and their expected timelines.
4Insights into operational efficiencies and cost management strategies.
5Any commentary on competitive pressures and market positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will look for signs of revenue growth as a measure of the company's market performance and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LQDA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+21.08%

Avg Stock Reaction

+4.49%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding product offerings in the respiratory market.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiencies to improve margins.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown strong EPS surprises in recent quarters, but revenue guidance remains unclear. Investors are eager to see if this trend continues.

Bull Case

If Liquidia can demonstrate continued profitability and strong revenue growth, it could solidify investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provide clear guidance, it may lead to a sell-off as investors reassess their outlook.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue for this quarter?

Revenue figures are crucial for assessing the company's growth trajectory and market acceptance of its products.

Will management provide guidance on future earnings?

Clear guidance can significantly influence investor sentiment and expectations for the upcoming quarters.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Liquidia's new product pipeline to drive significant revenue growth, given the recent positive EPS surprises.

Supporting Evidence

Liquidia has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a large move, suggesting traders expect a significant reaction that the consensus may not fully reflect.

The company's focus on expanding into new therapeutic areas could provide unexpected revenue streams.

Key Risk

If the reported revenue significantly exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether the recent positive EPS surprises can translate into sustained revenue growth.

Bull Confirmed If

Reporting revenue growth exceeding 20% year-over-year would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or lack of guidance would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±29.39%

Historical Avg

±6.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.4% while LQDA has averaged ±6.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

78.5%

Calls (67K)P/C Ratio: 0.18Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Liquidia beats expectations and raises guidance, history suggests a potential stock increase of around 6.54%, reinforcing bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 2.44%, leading to increased skepticism about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth and product sales in the respiratory market.
2Management's outlook on future earnings and any guidance provided.
3Updates on clinical trials and their expected timelines.
4Insights into operational efficiencies and cost management strategies.
5Any commentary on competitive pressures and market positioning.